Lupin (BOM:500257) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Lupin FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lupin's Free Cash Flow for the three months ended in Sep. 2024 was ₹0 Mil. Lupin's Revenue for the three months ended in Sep. 2024 was ₹54,970 Mil. Therefore, Lupin's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Lupin's current FCF Yield % is 2.74%.

The historical rank and industry rank for Lupin's FCF Margin % or its related term are showing as below:

BOM:500257' s FCF Margin % Range Over the Past 10 Years
Min: -45.5 Med: 5 Max: 14.79
Current: 12.96

During the past 13 years, the highest FCF Margin % of Lupin was 14.79%. The lowest was -45.50%. And the median was 5.00%.

BOM:500257's FCF Margin % is ranked better than
80.18% of 994 companies
in the Drug Manufacturers industry
Industry Median: 0.9 vs BOM:500257: 12.96

Lupin FCF Margin % Historical Data

The historical data trend for Lupin's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin FCF Margin % Chart

Lupin Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Margin %

Get a 7-Day Free Trial

5.25

7.66

-3.32

2.44

13.84

Lupin Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Lupin's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lupin's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lupin's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lupin's FCF Margin % falls into.

Lupin FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lupin's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	27194.6	/	196563.4
	=	13.84 %

Lupin's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	0	/	54970.1
	=	0.00 %

Lupin FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lupin's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lupin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (BOM:500257) » Definitions » FCF Margin %

Traded in Other Exchanges

LUPIN:India

Address

Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400055

Website

https://www.lupin.com

Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Lupin Headlines

No Headlines